Zdrowie i gospodarka · 10/02/2009
FDA Extends Comment Period for Bioequivalence Guidance on Vancomycin HCl
The FDA is extending the comment period for its draft guidance on bioequivalence studies for vancomycin HCl capsules until March 19, 2009, in response to requests from industry stakeholders.
Source: Federal Register — Food and Drug AdministrationOpen original release →